Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
AssigneeGeorgia Regents University
InventorsAhmed Chadli, Abdessamad Debbab, Peter Proksch
Life of this patent
Estimating the term…
Loading patent…
AssigneeGeorgia Regents University
InventorsAhmed Chadli, Abdessamad Debbab, Peter Proksch
Estimating the term…
Methods of inhibiting the Hsp90 chaperone pathway including contacting one or more target cells with an effective amount of a naturally occurring beauvericin, a synthetic beauvericin, or a derivative, analog or prodrug, or a pharmacologically active salt thereof to reduce, decrease, or inhibit the Hsp90 chaperone pathway in the cells compared to a control are disclosed. The methods can reduce the viability of the target cells, for example, by increasing apoptosis or pro-apoptotic pathways. In preferred embodiments, the methods reduce or do not increase Hsp70, Hsp24, Hsp40, or HOP expression; reduce or do not increase the heat shock response; reduce or do not increase pro-survival pathways in the cells. Methods of treating diseases such as cancer, inflammatory diseases or disorders, neurodegenerative diseases, and infectious diseases using the disclosed compositions and methods are also disclosed.
A method of inhibiting the Hsp90 chaperone pathway comprising contacting one or more cells expressing Hsp90 with an effective amount of a beauvericin, a derivative, analog, prodrug, or a pharmacologically active salt thereof to reduce, decrease, or inhibit the Hsp90 chaperone pathway in the cells compared to a control.
A method of treating cancer comprising administering to a subject with cancer an effective amount of a naturally occurring beauvericin, synthetic beauvericin, or derivative, analog or prodrug, or pharmacologically active salt thereof to reduce or inhibit one or more symptoms of the cancer.
A pharmaceutical composition comprising an effective amount of a naturally occurring beauvericin, a synthetic beauvericin, or a derivative, analog or prodrug, or a pharmacologically active salt thereof to reduce, decrease, to inhibit the Hsp90 chaperone pathway in cells of a subject compared to a control, and a pharmaceutically acceptable carrier.
The pharmaceutical composition of claim 17 further comprising one or more additional therapeutic agents.
Dependencies are inferred from the claim text.